Leandro Huayanay

Leandro Huayanay

Auto-generated profile, based on publicly available information

Leandro Huayanay

Facultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia, Lima, Peru

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2015 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
APAndres Pichon-Riviere
Andres Pichon-Riviere
OGOsvaldo Ulises Garay
Osvaldo Ulises Garay
FAFederico Augustovski
Federico Augustovski
CVCarlos Vallejos
Carlos Vallejos
LHLeandro Huayanay
Leandro Huayanay
MDMichael Drummond
Michael Drummond
Objectives:Differential pricing, based on countries’ purchasing power, is recommended by the World Health Organization to secure affordable medicines. However, in developing countries innovative drugs often have similar or even higher prices than in high-income countries. We evaluated the potential implications of trastuzumab global pricing policies in terms of cost-effectiveness (CE), coverage, and accessibility for patients with breast cancer in Latin America (LA).Methods:A Markov model was designed to estimate life-years (LYs), quality-adjusted life-years (QALYs), and costs from a healthcare perspective. To better fit local cancer prognosis, a base case scenario using transition probabilities from clinical trials was complemented with two alternative scenarios with transition probabilities adjusted to reflect breast cancer epidemiology in each country.Results:Incremental discounted benefits ranged from 0.87 to 1.00 LY and 0.51 to 0.60 QALY and incremental CE ratios from USD 42,104 to USD 110,283 per QALY (2012 U.S. dollars), equivalent to 3.6 gross domestic product per capita (GDPPC) per QALY in Uruguay and to 35.5 GDPPC in Bolivia. Probabilistic sensitivity analysis showed 0 percent probability that trastuzumab is CE if the willingness-to-pay threshold is one GDPPC per QALY, and remained so at three GDPPC threshold except for Chile and Uruguay (4.3 percent and 26.6 percent, respectively). Trastuzumab price would need to decrease between 69.6 percent to 94.9 percent to became CE in LA.Conclusions:Although CE in other settings, trastuzumab was not CE in LA. The use of health technology assessment to prioritize resource allocation and support price negotiations is critical to making innovative drugs available and affordable in developing countries.

30 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AFAldo De Ferrari
Aldo De Ferrari
CGCesar Gentille
Cesar Gentille
LDLong Davalos
Long Davalos
LHLeandro Huayanay
Leandro Huayanay
GMGerman Malaga
German Malaga
The interaction between physicians and the pharmaceutical industry influences physicians' attitudes and prescribing behavior. Although largely studied in the US, this topic has not been well studied in resource-poor settings, where a close relationship between physicians and industry still exists. To describe physician interactions with and attitudes towards the pharmaceutical industry in a public general hospital in Lima, Peru. Descriptive, cross-sectional study through an anonymous, self-filled questionnaire distributed among faculty and trainee physicians of five different clinical departments working in a Peruvian public general hospital. A transcultural validation of an existing Spanish questionnaire was performed. Exposure to marketing activities, motivations to contact pharmaceutical representatives and attitudes towards industry were studied. Collected data was analyzed by degree of training, clinical department, gender and teaching status. Attitudes were measured on a four-point LIKERT scale. 155 physicians completed the survey, of which 148 were included in the study sample. 94.5% of attending physicians reported ongoing encounters with pharmaceutical representatives. The most common industry-related activities were receiving medical samples (91.2%), promotional material (87.8%) and attending meetings in restaurants (81.8%). Respondents considered medical samples and continuing medical education the most ethically acceptable benefits. We found significant differences between attendings and residents, and teaching and non-teaching attendings. An association between the amount of encounters with pharmaceutical representatives, and attitudes towards industry and acceptance of medical samples was found. A close physician-industry relationship exists in the population under study. The contact is established mainly through pharmaceutical representatives. Medical samples are the most received and ethically accepted benefit. The attitudes of physicians on the ethical standards of acceptance of medical samples and other benefits are closely related with their exposure to the pharmaceutical industry. Future studies could explore the motivations of physicians working in resource-poor settings to maintain a close relationship with industry.

30 January 2011 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
EREdmundo Rosales-Mayor
Edmundo Rosales-Mayor
JCJorge Rey de Castro
Jorge Rey de Castro
LHLeandro Huayanay
Leandro Huayanay
KZKenny Zagaceta
Kenny Zagaceta

13 December 2016 in Revista Peruana de Medicina Experimental Y Salud Pública
Verified
Journal Article
Open access
Ariel BardachAriel Bardach
Ariel Bardach
JCJoaquín E. Caporale
Joaquín E. Caporale
AAAndrea Alcaraz
Andrea Alcaraz
FAFederico Augustovski
Federico Augustovski
LHLeandro Huayanay-Falconí
Leandro Huayanay-Falconí
APAndrés Pichon-Riviere
Andrés Pichon-Riviere
. To calculate the burden of smoking-related disease and evaluate the potential economic and health impact of tax-induced cigarette price increase in Peru. A microsimulation model was used to estimate smoking-attributable impact on mortality, quality of life, and costs associated with heart and cerebrovascular disease, chronic obstructive pulmonary disease, pneumonia, lung cancer, and another nine cancers. Three scenarios, involving increased taxes, were evaluated. . A yearly total of 16,719 deaths, 6,926 cancer diagnoses, 7,936 strokes, and 7,548 hospital admissions due to cardiovascular disease can be attributed to smoking in Peru. Similarly, 396,069 years of life are lost each year from premature death and disability, and the cost of treating smoking-attributable health issues rises to 2,500 million soles (PEN 2015). Currently, taxes on tobacco cover only 9.1% of this expense. If cigarette prices were to increase by 50% over the next 10 years, 13,391 deaths, 6,210 cardiovascular events, and 5,361 new cancers could be prevented, representing an economic benefit of 3,145 million (PEN) in savings in health costs and increases in tax revenues. . Smoking-attributable burden of disease and costs to the health system are very high in Peru. Higher cigarette taxes could have substantial health and economic benefits for the country.

1 October 2006 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FOFernando Osores
Fernando Osores
ONOscar Nolasco
Oscar Nolasco
KVKristien Verdonck
Kristien Verdonck
JAJorge Arevalo
Jorge Arevalo
JFJuan Carlos Ferrufino
Juan Carlos Ferrufino
CMCiro Maguina
Ciro Maguina
Reports on the sensitivity of polymerase chain reaction (PCR) for the diagnosis of lymph node tuberculosis (TB) show divergent results. We evaluated

1 September 2011 in Revista Peruana de Medicina Experimental Y Salud Pública
Verified
Journal Article
Closed access
PDF file
CLCesar Loza
Cesar Loza
MCManuel Castillo-Portilla
Manuel Castillo-Portilla
JRJosé Luis Rojas
José Luis Rojas
LHLeandro Huayanay
Leandro Huayanay
Health Economics is an essential instrument for health management, and economic evaluations can be considered as tools assisting the decision-making process for the allocation of resources in health. Currently, economic evaluations are increasingly being used worldwide, thus encouraging evidence-based decision-making and seeking efficient and rational alternatives within the framework of health services activities. In this review, we present an overview and define the basic types of economic evaluations, with emphasis on complete Economic Evaluations (EE). In addition, we review key concepts regarding the perspectives from which EE can be conducted, the types of costs that can be considered, the time horizon, discounting, assessment of uncertainty and decision rules. Finally, we describe concepts about the extrapolation and spread of economic evaluations in health.